Nektar Therapeutics (NKTR) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 4, 2026, with virtual participation available to shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 3, 2026.

Voting matters and shareholder proposals

• Election of Howard W. Robin as director is up for shareholder vote, with board recommending approval.

• Proposal to amend the 2017 Performance Incentive Plan to add 3,000,000 shares for issuance.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay) included, with board recommending approval.

Board of directors and corporate governance

• Board recommends approval of all proposals presented for shareholder vote.